Patient 10, despite having a favorable CD8+ T cell percentage, had a high proportion of myeloid cells, likely including suppressive tumor‐associated macrophages, which may have contributed to a diminished response (Figure S14, Supporting Information).[33] Overall, MATCH treatment significantly reduced MM cell percentages compared to untreated controls in 13 out of 16 patients, underscoring its potential for effective MM targeting (Figure 7E). This evidence concerns the gene CD8A and neoplasm.